Panelist
Clive Bates
Clive Bates
- Panelist
- United Kingdom
Clive Bates has had a diverse career in the public, private and not-for-profit sectors. Starting out with IBM, he then switched career to work in the environment movement. From 1997-2003 he was Director of Action on Smoking and Health (UK), campaigning to reduce the harms caused by tobacco. In 2003 he joined Prime Minister Tony Blair’s Strategy Unit as a civil servant and worked in senior roles in the public sector and for the United Nations in Sudan. He is now Director of The Counterfactual, a consulting and advocacy practice focussed on a pragmatic approach to sustainability and public health.
Panelist
Roberto Sussman
Roberto Sussman
- Panelist
- Mexico
Dr Roberto A Sussman (PhD University of London) is a full time senior researcher and lecturer at the Institute for Nuclear Sciences of the National University of Mexico. His main research areas are General Relativity and Cosmology, but he has conducted research in other areas of Physics, including peer reviewed publications on e-cigarette aerosols. He is also the founder and Director of Pro-Vapeo Mexico, an association representing Mexican consumers of noncombustible nicotine products and is a member of INNCO. He is actively advocating for an appropriate regulation of Tobacco Harm Reduction products in Mexico. He directs and supervises the effort to spread scientific information on these products, as well as advising consumers on how to counter the governmental misinformation and prejudice about them that is rampant throughout Latin America.
Panelist
Marewa Glover
Marewa Glover
- Panelist
- New Zealand
Professor Marewa Glover is one of New Zealand’s leading tobacco control researchers. She has worked on reducing smoking-related harm for 31 years. She is recognized internationally for her advocacy on tobacco harm reduction; and locally was a Finalist in the New Zealander of the Year Supreme Award in 2019 recognising her contribution to reducing smoking in NZ. In 2018, Dr Glover was appointed Tobacco Section Editor for the Harm Reduction Journal. In that year she also established the Centre of Research Excellence: Indigenous Sovereignty & Smoking, an international program of research aimed at reducing smoking-related harms among Indigenous peoples globally. The Centre’s research was funded with grants from the Foundation for a Smoke-Free World, Inc. (“FSFW”), a US nonprofit 501(c)(3) private foundation.
Panelist
Moira Gilchrist
Moira Gilchrist
- Panelist
- Switzerland
Dr. Moira Gilchrist leads the global strategic and scientific communications for Philip Morris International (PMI). From bringing to life PMI’s fast-pace progress as it evolves into a smoke-free business and expands in areas outside the tobacco and nicotine space, to translating the science behind PMI’s smoke-free alternatives into information that policymakers and the public can easily understand, Moira and her team are at the heart of the company’s historic evolution. She regularly engages with public health authorities, media, and decision-makers around the world, demonstrating the benefits of scientifically substantiated, smoke-free products for those adults who would otherwise continue smoking and calling for risk-proportionate regulation that affords these people accurate information about and access to these better alternatives. In short, she plays a vital role in PMI’s transition away from cigarettes and its journey toward a better, smoke-free future.
Prior to her current role, Moira held several positions within PMI, including leading the
Reduced-Risk Products Corporate Affairs team, serving as director of Scientific
Engagement within the R&D function, and working in both product development and
commercialization.
Before joining PMI in 2006, Moira worked in the pharmaceutical sector for more than a
decade. She was a principal consultant within PwC’s and IBM’s pharmaceutical industry
consulting groups and held positions within both industry and nonprofit organizations as
a developer of drug formulations.
Moira holds a degree in Pharmacy and a PhD in Pharmaceutical Sciences, both from the
University of Strathclyde in Glasgow, Scotland.
Panelist
David Abrams